Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and LakePharma, Inc., the leading US-based biologics CRDMO, today announced a strategic collaboration to offer antibody discovery and development solutions to pharmaceutical and biotechnology customers.
Clinical-stage biopharmaceutical firm Xencor has entered into a research collaboration with Astellas Pharma for novel bispecific antibody program.
Swiss pharma giant Novartis has agreed to acquire IFM Tre from US biopharma company IFM Therapeutics in a deal worth up to $1.575bn, to add certain immunomodulatory medicines to its portfolio.
Puma Biotechnology, Inc. (Nasdaq: PBYI) and Pierre Fabre have entered into an exclusive license agreement under which Pierre Fabre will develop and commercialize NERLYNX (neratinib) within Europe and part of Africa.
Boehringer Ingelheim has acquired MacroDel biologics-delivery platform developer, ICD Therapeutics, for an undisclosed amount.
Major drugmaker AstraZeneca has entered into a $6.9bn cancer deal with Japanese pharmaceutical firm Daiichi Sankyo.
Cancer Research UK has entered into a multi-year partnership with LifeArc and Ono Pharmaceutical to identify new immunotherapy drug targets for cancer.
Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF‐platform compounds.
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors and BioInvent International AB, a biotech company focused on the discovery and development of novel immuno-regulatory antibodies to treat cancer, announce the extension of their collaboration to co-develop multi-functional oncolytic viruses (OV) encoding for undisclosed antibodies sequences capable of treating a broad range of solid tumors.
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced a successful $50 million Series B financing.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.